Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Biosimilars set for huge sales growth if regulatory hurdles can be ovecome

Kalorama Information : 23 April, 2008  (Company News)
A huge potential market for biosimilars is about to open up, if regulatory hurdles can be overcome, according to a new report released by Kalorama Information, Biogenerics: the World Market for Biosimilars.
Some of the biggest-selling biologics developed during the boom years in biotech of the 1980s, including human growth hormone (hGH) and insulin, have lost patent protection in the USA in 2007 or will shortly, and they represent a market of $40 billion.

Worldwide interest in biosimilars is gaining momentum and is expected to reach $5.8 billion by 2012. But first such stumbling blocks as safety, access to innovators’ key intermediates, process controls, availability and access to bulk materials, specifically designed and adapted analytical procedures and validation studies must be addressed. Also, biosimilars cannot currently be marketed in the USA because there is no pathway for them to reach the market.

“Right now, there is limited competition in biosimilars due to the complicated regulatory process and the high costs,” noted Mary Anne Crandall, senior analyst for Kalorama. “But this won't last forever, and in fact in the near-term we should see some technological changes and political shifts that will fuel the market.'

Biosimilars have been selling outside of the USA for years, creating a small existing market. As the industry is allowed in the USA, which Kalorama predicts will happen in a serious way by 2009, it will grow exponentially. Growth will likely occur around a few big biopharmaceuticals at first.

Kalorama Information’s report Biogenerics: the World Market for Biosimilars identifies the biopharmaceuticals that have lost patent protection and are likely to be the first products attempted by generic companies. Current and future trends, market size and projections are also provided.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo